This study examines how a new drug, called AR1001, might help people with early Alzheimer's Disease (AD). Alzheimer's affects the brain, causing memory problems and confusion. AR1001 is a small molecule, which means it's a tiny substance that could help treat the disease by working in different ways to improve brain health.

• **Duration:** The study might take several months, with regular doctor visits.
• **Eligibility:** Participants should be 55-90 years old with mild memory problems.
• **Risks:** Some people may have side effects or not see improvements.

Participants must have a supportive adult who knows them well to help report on their condition. Some people cannot join, such as those with severe health issues, certain psychiatric conditions, or recent cancer. This study is important to see if AR1001 can be a new treatment for Alzheimer's.